Send us Feedback

Novo Nordisk A/S (NVO)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Novo Nordisk A/S : Victoza(R) label in the US updated to include data showing superior efficacy when compared to Januvia(R)
Marketwire  Apr 6  Comment 
BAGSVAERD, DENMARK -- (Marketwire) -- 04/06/12 -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved to update the product label for Victoza® (liraglutide [rDNA] injection) to include data showing superior blood
Lundbeckfond contributes to $25M B round for AlloCure's Phase II stem cell study
FierceBiotech  Apr 2  Comment 
New investor Lundbeckfond Ventures has contributed to a $25 million venture round for AlloCure, a Burlington, MA-based stem cell company. The Series B cash will be used to advance AC607--AlloCure's lead program--into a mid-stage study for acute...
FDA Approves Levemir® Pregnancy Category Change for Women with Diabetes
PR Newswire  Apr 2  Comment 
PRINCETON, N.J., April 2, 2012 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that the U.S. Food and Drug Administration (FDA) has approved Levemir(®) (insulin detemir [rDNA origin] injection) for a pregnancy Category
Novo Nordisk A/S : Status regarding Novo Nordisk's holding of its own shares (31 March 2012)
Marketwire  Apr 2  Comment 
BAGSVAERD, DENMARK -- (Marketwire) -- 04/02/12 -- In continuation of the company's announcements dated 2 November 2011 and 2 February 2012 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange
Novo Nordisk A/S: Novo Nordisk A/S - Share repurchase programme
Marketwire  Apr 2  Comment 
Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme
Marketwire  Mar 26  Comment 
BAGSVAERD, DENMARK -- (Marketwire) -- 03/26/12 -- On 2 February 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as
Novo Energies Corporation Announces Immunovative Therapies, Ltd. Appointment of Asia Global Research Co., Ltd. as CRO for Clinical Trial Program in Bangkok, Thailand
Marketwire  Mar 21  Comment 
NEW YORK, NY -- (Marketwire) -- 03/21/12 -- Novo Energies Corporation ("Novo") (OTCBB: NVNC) today announced that Immunovative Therapies, Ltd. ("Immunovative") is preparing to launch a potentially pivotal, randomized, controlled Phase II/III clinical
PROLOR Biotech Initiates Phase II Trial of its Long-Acting Human Growth Hormone in Children with Growth Hormone Deficiency
Benzinga  Mar 20  Comment 
PROLOR Biotech, Inc. (NYSE: PBTH) today announced initiation of a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in children with growth hormone deficiency. The pediatric trial follows...
VCs rally behind Tarsa Therapeutics in $28M B round
FierceBiotech  Mar 16  Comment 
Tarsa Therapeutics has scooped up the capital it needs to seek approvals of its first drug. The developer has raised $28 million in a second-round financing to advance an application for FDA approval of its calcitonin tablet for women with...
Novo Energies Corporation Announces the Appointment of Immunovative Therapies, Ltd.'s GCP and GMP Experts
Marketwire  Mar 15  Comment 
NEW YORK, NY -- (Marketwire) -- 03/15/12 -- Novo Energies Corporation ("Novo") (OTCBB: NVNC) today announced that Immunovative Therapies, Ltd. ("Immunovative") has retained the services of Andra E. Miller, Ph.D. and Holly M. Scott of Biologics
Novo seen to benefit from Pfizer-Biocon split
FiercePharma  Mar 14  Comment 
Pfizer ($PFE) and Biocon's decision to dissolve their partnership was bad news for the Indian company's stock, as analysts downgraded their sales estimates for its insulin products. But Novo Nordisk ($NVO), the Danish diabetes specialist, got a...




more ▼WIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


You may also be interested in articles related to Novo Nordisk A/S (NVO):
 




References

Retrieved from "http://www.wikinvest.com/stock/Novo_Nordisk_A/S_(NVO)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki